Pharmaceutical Technology

APRIL 26, 2023

Today’s digital inhaler space requires “consistent engagement over an extended timeframe,” says Francis White, global vice president of business development at Adherium , along with “showing commitment while continuing to prove the patient benefits, cost reductions, and reduction of staff burden.”

Clinical Trials 289

Clinical Trials Clinical Trials Research Allergies 289

pharmaphorum

OCTOBER 1, 2021

The debut – raising upwards of £350 million from new shares – is the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014. Chief technology officer Clive Brown is also sitting on a £10 million stake. .” The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.

Marketing 52

Marketing Genomics Genome Business Development 52

pharmaphorum

DECEMBER 9, 2021

Johnson & Johnson Consumer Health focuses its external innovation efforts on Self Care, which consists of allergy, smoking cessation, pain, digestive health, and cough and cold; and Skin Health, which includes acne, sensitive skin, skin protection and aging skin support.

Allergies 105

Allergies Life Science Development Scientist 105

The Pharma Data

AUGUST 30, 2021

Malik succeeds John Young, Executive Vice President and Chief Business Officer, who recently announced his intent to retire after a 34-year career at Pfizer. Malik earned a Bachelor of Science in finance from Indiana University and currently serves on the University’s Kelley School of Business Dean’s Council.

Allergies 52

Allergies Life Science Business Development Development 52

The Pharma Data

JANUARY 3, 2021

Magnus Kjellberg, CEO and co-president, and Gennaro Falanga, co-president, stated: “Over the past few years, we have built up a science-driven, global business spanning 70 worldwide countries dedicated to healthy, vibrant pets for life. We have a particular passion for allergy, dermatology and specialized care, and specialized nutrition.

Dermatology 40

Dermatology Allergies Branding Business Development 40

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. in the Allergy & Cold category. percent (Fx & portfolio adj.) This led to a decline of 30.1

Sales 40

Sales Production Marketing Containment 40